Text this: RITONAVIR-BASED ANTI-RETROVIRAL THERAPY IS ASSOCIATED WITH A LOWER EJECTION FRACTION AND AN INCREASED RISK FOR DECOMPENSATED HEART FAILURE AND CARDIOVASCULAR MORTALITY AMONG PERSONS LIVING WITH HIV.